{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:49:22Z","timestamp":1792784962818,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"4SC AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In hepatocellular carcinoma (HCC), blood platelets have been linked to tumor growth, epithelial-to-mesenchymal transition (EMT), extrahepatic metastasis and a limited therapeutic response to the multikinase inhibitor (MKi) sorafenib, the standard of care in advanced HCC for the last decade. Recent clinical data indicated an improved overall survival for sorafenib in combination with the HDAC inhibitor resminostat in a platelet count dependent manner. Here, the impact of platelets on the sorafenib and resminostat drug effects in HCC cells was explored. In contrast to sorafenib, resminostat triggered an anti-proliferative response in HCC cell lines independent of platelets. As previously described, platelets induced invasive capabilities of HCC cells, a prerequisite for extravasation and metastasis. Importantly, the resminostat\/sorafenib drug combination, but not the individual drugs, effectively blocked platelet-induced HCC cell invasion. Exploration of the molecular mechanism revealed that the combined drug action led to a reduction of platelet-induced\n                    <jats:italic>CD44<\/jats:italic>\n                    expression and to the deregulation of several other epithelial and mesenchymal genes, suggesting interference with cell invasion via EMT. In addition, the drug combination decreased phosphorylated ERK level, indicating inhibition of the mitogenic signaling pathway MEK\/ERK. Taken together, the resminostat plus sorafenib combination counteracts platelet-mediated cancer promoting effects in HCC cells.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-88983-1","type":"journal-article","created":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T06:07:04Z","timestamp":1620194824000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma"],"prefix":"10.1038","volume":"11","author":[{"given":"Gundula","family":"Streubel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Schrepfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Kallus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Parnitzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Wulff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Borgmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Hamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,5]]},"reference":[{"key":"88983_CR1","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"PR Galle","year":"2018","unstructured":"Galle, P. R. et al. EASL clinical practice guidelines: Management of hepatocellular carcinoma. J. Hepatol. 69, 182\u2013236 (2018).","journal-title":"J. Hepatol."},{"key":"88983_CR2","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","volume":"15","author":"JM Llovet","year":"2018","unstructured":"Llovet, J. M., Montal, R., Sia, D. & Finn, R. S. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 15, 599\u2013616 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"88983_CR3","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378\u2013390 (2008).","journal-title":"N. Engl. J. Med."},{"key":"88983_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"A-L Cheng","year":"2009","unstructured":"Cheng, A.-L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25\u201334 (2009).","journal-title":"Lancet Oncol."},{"key":"88983_CR5","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3390\/cancers10110412","volume":"10","author":"M Kudo","year":"2018","unstructured":"Kudo, M. Systemic therapy for hepatocellular carcinoma: Latest advances. Cancers (Basel) 10, 412 (2018).","journal-title":"Cancers (Basel)"},{"key":"88983_CR6","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1136\/gutjnl-2016-313462","volume":"66","author":"C Berasain","year":"2017","unstructured":"Berasain, C. & Lechel, A. Targeting the correct target in HCC. Gut 66, 1352\u20131354 (2017).","journal-title":"Gut"},{"key":"88983_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers11101568","volume":"11","author":"Q Lai","year":"2019","unstructured":"Lai, Q. et al. Platelets and hepatocellular cancer: Bridging the bench to the clinics. Cancers (Basel) 11, 1\u201322 (2019).","journal-title":"Cancers (Basel)"},{"key":"88983_CR8","first-page":"1","volume":"5","author":"Y Yilmaz","year":"2016","unstructured":"Yilmaz, Y., Erdal, E., Atabey, N. & Carr, B. I. Platelets, microenvironment and hepatocellular carcinoma. Biochem. Anal. Biochem. 5, 1\u20138 (2016).","journal-title":"Biochem. Anal. Biochem."},{"key":"88983_CR9","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/apm.12574","volume":"124","author":"C Bihari","year":"2016","unstructured":"Bihari, C. et al. Platelets contribute to growth and metastasis in hepatocellular carcinoma. APMIS 124, 776\u2013786 (2016).","journal-title":"APMIS"},{"key":"88983_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cca.2018.04.023","volume":"483","author":"B Li","year":"2018","unstructured":"Li, B. et al. Platelet-to-lymphocyte ratio in advanced Cancer: Review and meta-analysis. Clin. Chim. Acta 483, 48\u201356 (2018).","journal-title":"Clin. Chim. Acta"},{"key":"88983_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","volume":"21","author":"D Hanahan","year":"2012","unstructured":"Hanahan, D. & Coussens, L. M. Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309\u2013322 (2012).","journal-title":"Cancer Cell"},{"key":"88983_CR12","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ccell.2018.03.002","volume":"33","author":"M Haemmerle","year":"2018","unstructured":"Haemmerle, M., Stone, R. L., Menter, D. G., Afshar-Kharghan, V. & Sood, A. K. The platelet lifeline to cancer: Challenges and opportunities. Cancer Cell 33, 965\u2013983 (2018).","journal-title":"Cancer Cell"},{"key":"88983_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11020240","author":"PT Huong","year":"2019","unstructured":"Huong, P. T., Nguyen, L. T., Nguyen, X. B., Lee, S. K. & Bach, D. H. The role of platelets in the tumor-microenvironment and the drug resistance of cancer cells. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers11020240 (2019).","journal-title":"Cancers (Basel)"},{"key":"88983_CR14","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/j.1476-5381.2012.01991.x","volume":"167","author":"C Medina","year":"2012","unstructured":"Medina, C. et al. Platelets increase survival of adenocarcinoma cells challenged with anticancer drugs: Mechanisms and implications for chemoresistance. Br. J. Pharmacol. 167, 787\u2013804 (2012).","journal-title":"Br. J. Pharmacol."},{"key":"88983_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-14-351","volume":"14","author":"R D\u2019Alessandro","year":"2014","unstructured":"D\u2019Alessandro, R. et al. Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines. BMC Cancer 14, 1\u20139 (2014).","journal-title":"BMC Cancer"},{"key":"88983_CR16","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1517\/14656566.2015.1101065","volume":"16","author":"R D\u2019Alessandro","year":"2015","unstructured":"D\u2019Alessandro, R., Messa, C., Refolo, M. G. & Carr, B. I. Modulation of sensitivity and resistance to multikinase inhibitors by microenvironmental platelet factors in HCC. Expert Opin. Pharmacother. 16, 2773\u20132780 (2015).","journal-title":"Expert Opin. Pharmacother."},{"key":"88983_CR17","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.suronc.2018.07.015","volume":"27","author":"DI Tsilimigras","year":"2018","unstructured":"Tsilimigras, D. I., Ntanasis-Stathopoulos, I., Moris, D., Spartalis, E. & Pawlik, T. M. Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective. Surg. Oncol. 27, 611\u2013618 (2018).","journal-title":"Surg. Oncol."},{"key":"88983_CR18","doi-asserted-by":"publisher","first-page":"158","DOI":"10.7150\/jca.4211","volume":"3","author":"S Gahr","year":"2012","unstructured":"Gahr, S. et al. Combination of the deacetylase inhibitor panobinostat and the mul-ti-kinase inhibitor sorafenib for the treatment of metastatic hepatocellu-lar carcinoma: Review of the underlying molecular mechanisms and first case report. J. Cancer 3, 158\u2013165 (2012).","journal-title":"J. Cancer"},{"key":"88983_CR19","doi-asserted-by":"publisher","first-page":"12059","DOI":"10.3748\/wjg.v21.i42.12059","volume":"21","author":"JJ Gao","year":"2015","unstructured":"Gao, J. J., Shi, Z. Y., Xia, J. F., Inagaki, Y. & Tang, W. Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. World J. Gastroenterol. 21, 12059\u201312070 (2015).","journal-title":"World J. Gastroenterol."},{"key":"88983_CR20","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jhep.2016.02.043","volume":"65","author":"M Bitzer","year":"2016","unstructured":"Bitzer, M. et al. Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma: The SHELTER study. J. Hepatol. 65, 280\u2013288 (2016).","journal-title":"J. Hepatol."},{"key":"88983_CR21","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1007\/s10637-018-0658-x","volume":"36","author":"WY Tak","year":"2018","unstructured":"Tak, W. Y. et al. Phase I\/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients. Invest. New Drugs 36, 1072\u20131084 (2018).","journal-title":"Invest. New Drugs"},{"key":"88983_CR22","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1365-2141.2010.08124.x","volume":"149","author":"S Mandl-Weber","year":"2010","unstructured":"Mandl-Weber, S. et al. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. Br. J. Haematol. 149, 518\u2013528 (2010).","journal-title":"Br. J. Haematol."},{"key":"88983_CR23","doi-asserted-by":"publisher","first-page":"110367","DOI":"10.18632\/oncotarget.22775","volume":"8","author":"J Soukupova","year":"2017","unstructured":"Soukupova, J. et al. Resminostat induces changes in epithelial plasticity of hepatocellular carcinoma cells and sensitizes them to sorafenib-induced apoptosis. Oncotarget 8, 110367\u2013110379 (2017).","journal-title":"Oncotarget"},{"key":"88983_CR24","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/hed.24699","volume":"39","author":"E Enzenhofer","year":"2017","unstructured":"Enzenhofer, E. et al. Effect of the histone deacetylase inhibitor resminostat on head and neck squamous cell carcinoma cell lines. Head Neck 39, 900\u2013907 (2017).","journal-title":"Head Neck"},{"key":"88983_CR25","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1128\/MCB.01500-09","volume":"30","author":"G Zupkovitz","year":"2010","unstructured":"Zupkovitz, G. et al. The cyclin-dependent kinase inhibitor p21 is a crucial target for histone deacetylase 1 as a regulator of cellular proliferation. Mol. Cell. Biol. 30, 1171\u20131181 (2010).","journal-title":"Mol. Cell. Biol."},{"key":"88983_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms18071414","volume":"18","author":"T Eckschlager","year":"2017","unstructured":"Eckschlager, T., Plch, J., Stiborova, M. & Hrabeta, J. Histone deacetylase inhibitors as anticancer drugs. Int. J. Mol. Sci. 18, 1\u201325 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"88983_CR27","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm, S. M. et al. BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the RAF \/ MEK \/ ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the Pr. Cancer Res. 64, 7099\u20137109 (2004).","journal-title":"Cancer Res."},{"key":"88983_CR28","first-page":"2719","volume":"9","author":"X Yao","year":"2003","unstructured":"Yao, X. et al. A novel orthotopic tumor model to study growth factors and oncogenes in hepatocarcinogenesis. Clin. Cancer Res. 9, 2719\u20132726 (2003).","journal-title":"Clin. Cancer Res."},{"key":"88983_CR29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.canlet.2012.10.021","volume":"329","author":"H van Malenstein","year":"2013","unstructured":"van Malenstein, H. et al. Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth. Cancer Lett. 329, 74\u201383 (2013).","journal-title":"Cancer Lett."},{"key":"88983_CR30","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.jhep.2016.05.007","volume":"65","author":"G Giannelli","year":"2016","unstructured":"Giannelli, G., Koudelkova, P., Dituri, F. & Mikulits, W. Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J. Hepatol. 65, 798\u2013808 (2016).","journal-title":"J. Hepatol."},{"key":"88983_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-018-0080-4","author":"A Dongre","year":"2018","unstructured":"Dongre, A. & Weinberg, R. A. New insights into the mechanisms of epithelial\u2013mesenchymal transition and implications for cancer. Nat. Rev. Mol. Cell. Biol. https:\/\/doi.org\/10.1038\/s41580-018-0080-4 (2018).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"88983_CR32","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1158\/0008-5472.CAN-07-2460","volume":"68","author":"BC Fuchs","year":"2008","unstructured":"Fuchs, B. C. et al. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res. 68, 2391\u20132399 (2008).","journal-title":"Cancer Res."},{"key":"88983_CR33","doi-asserted-by":"publisher","first-page":"E161","DOI":"10.1002\/ijc.29097","volume":"136","author":"J Fernando","year":"2015","unstructured":"Fernando, J. et al. A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells. Int. J. Cancer 136, E161\u2013E172 (2015).","journal-title":"Int. J. Cancer"},{"key":"88983_CR34","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1476-4598-8-90","volume":"8","author":"H Yuzugullu","year":"2009","unstructured":"Yuzugullu, H. et al. Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells. Mol. Cancer 8, 90 (2009).","journal-title":"Mol. Cancer"},{"key":"88983_CR35","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ccr.2011.09.009","volume":"20","author":"M Labelle","year":"2011","unstructured":"Labelle, M., Begum, S. & Hynes, R. O. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20, 576\u2013590 (2011).","journal-title":"Cancer Cell"},{"key":"88983_CR36","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41568-019-0213-x","volume":"19","author":"ED Williams","year":"2019","unstructured":"Williams, E. D., Gao, D., Redfern, A. & Thompson, E. W. Controversies around epithelial\u2013mesenchymal plasticity in cancer metastasis. Nat. Rev. Cancer 19, 716\u2013732 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"88983_CR37","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1002\/ijc.24868","volume":"126","author":"Z Zhu","year":"2010","unstructured":"Zhu, Z. et al. Cancer stem\/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int. J. Cancer 126, 2067\u20132078 (2010).","journal-title":"Int. J. Cancer"},{"key":"88983_CR38","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/cr.2011.139","volume":"22","author":"Y Hou","year":"2012","unstructured":"Hou, Y., Zou, Q., Ge, R., Shen, F. & Wang, Y. The critical role of CD133+CD44+\/hightumor cells in hematogenous metastasis of liver cancers. Cell Res. 22, 259\u2013272 (2012).","journal-title":"Cell Res."},{"key":"88983_CR39","doi-asserted-by":"publisher","first-page":"4873","DOI":"10.1038\/onc.2012.505","volume":"32","author":"Y Suh","year":"2013","unstructured":"Suh, Y. et al. Claudin-1 induces epithelial-mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells. Oncogene 32, 4873\u20134882 (2013).","journal-title":"Oncogene"},{"key":"88983_CR40","first-page":"2254","volume":"8","author":"Z Liu","year":"2018","unstructured":"Liu, Z. et al. Inhibitor of binding\/differentiation 2 (Id2) is regulated by CCAAT\/enhancer-binding protein-\u03b1 (C\/EBP\u03b1) and promotes the proliferation of hepatocellular carcinoma. Am. J. Cancer Res. 8, 2254\u20132266 (2018).","journal-title":"Am. J. Cancer Res."},{"key":"88983_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2047-783X-18-52","volume":"18","author":"G Lv","year":"2013","unstructured":"Lv, G. et al. RNA interference targeting human integrin \u03b16 suppresses the metastasis potential of hepatocellular carcinoma cells. Eur. J. Med. Res. 18, 1\u20138 (2013).","journal-title":"Eur. J. Med. Res."},{"key":"88983_CR42","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.3892\/ol.2016.5110","volume":"12","author":"L Li","year":"2016","unstructured":"Li, L. et al. The Ras\/Raf\/MEK\/ERK signaling pathway and its role in the occurrence and development of HCC (Review). Oncol. Lett. 12, 3045\u20133050 (2016).","journal-title":"Oncol. Lett."},{"key":"88983_CR43","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ijc.25864","volume":"129","author":"SM Wilhelm","year":"2011","unstructured":"Wilhelm, S. M. et al. Regorafenib (BAY 73\u20134506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int. J. Cancer 129, 245\u2013255 (2011).","journal-title":"Int. J. Cancer"},{"key":"88983_CR44","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.1158\/1078-0432.CCR-07-5270","volume":"14","author":"J Matsui","year":"2008","unstructured":"Matsui, J. et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin. Cancer Res. 14, 5459\u20135465 (2008).","journal-title":"Clin. Cancer Res."},{"key":"88983_CR45","doi-asserted-by":"publisher","first-page":"6342","DOI":"10.1021\/jm2007613","volume":"54","author":"JJ Cui","year":"2011","unstructured":"Cui, J. J. et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J. Med. Chem. 54, 6342\u20136363 (2011).","journal-title":"J. Med. Chem."},{"key":"88983_CR46","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc1779","volume":"6","author":"S Minucci","year":"2006","unstructured":"Minucci, S. & Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer. 6, 38\u201351 (2006).","journal-title":"Nat. Rev. Cancer."},{"key":"88983_CR47","first-page":"1","volume":"3","author":"Y Li","year":"2016","unstructured":"Li, Y. & Seto, E. HDACs and HDAC inhibitors in cancer. Cold Spring Harb. Perspect. Med. 3, 1\u201310 (2016).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"88983_CR48","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.7150\/ijbs.27661","volume":"14","author":"B He","year":"2018","unstructured":"He, B. et al. The HDAC Inhibitor Quisinostat (JNJ-26481585) Supresses Hepatocellular Carcinoma alone and Synergistically in Combination with Sorafenib by G0\/G1 phase arrest and Apoptosis induction. Int. J. Biol. Sci. 14, 1845\u20131858 (2018).","journal-title":"Int. J. Biol. Sci."},{"key":"88983_CR49","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.jhep.2012.01.009","volume":"56","author":"A Lachenmayer","year":"2012","unstructured":"Lachenmayer, A. et al. Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J. Hepatol. 56, 1343\u20131350 (2012).","journal-title":"J. Hepatol."},{"key":"88983_CR50","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1158\/1078-0432.CCR-12-3909","volume":"20","author":"CH Chen","year":"2014","unstructured":"Chen, C. H. et al. Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo. Clin. Cancer Res. 20, 1274\u20131287 (2014).","journal-title":"Clin. Cancer Res."},{"key":"88983_CR51","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx369.090","author":"G Meinhardt","year":"2017","unstructured":"Meinhardt, G., De Sanctis, Y., LeBerre, M.-A. & Nakajima, K. 706POverall survival (OS) by platelet count at baseline in patients with hepatocellular carcinoma (HCC) treated with sorafenib (SOR) in the SHARP and AP trials and regorafenib (REG) in the RESORCE trial. Ann. Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdx369.090 (2017).","journal-title":"Ann. Oncol."},{"key":"88983_CR52","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/jcp.24148","volume":"228","author":"BI Carr","year":"2013","unstructured":"Carr, B. I. et al. Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: Growth inhibition, quiescence, and recovery. J. Cell Physiol. 228, 292\u2013297 (2013).","journal-title":"J. Cell Physiol."},{"key":"88983_CR53","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","volume":"7","author":"SM Wilhelm","year":"2008","unstructured":"Wilhelm, S. M. et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7, 3129\u20133140 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"88983_CR54","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.currproblcancer.2013.06.001","volume":"37","author":"W Jeong","year":"2013","unstructured":"Jeong, W., Doroshow, J. H. & Kummar, S. United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies. Curr. Probl. Cancer 37, 110\u2013144 (2013).","journal-title":"Curr. Probl. Cancer"},{"key":"88983_CR55","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1471-2407-14-43","volume":"14","author":"BI Carr","year":"2014","unstructured":"Carr, B. I. et al. Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro. BMC Cancer 14, 43 (2014).","journal-title":"BMC Cancer"},{"key":"88983_CR56","doi-asserted-by":"publisher","first-page":"60609","DOI":"10.18632\/oncotarget.11300","volume":"7","author":"R Zhang","year":"2016","unstructured":"Zhang, R. et al. Activated platelets inhibit hepatocellular carcinoma cell differentiation and promote tumor progression via platelet-tumor cell binding. Oncotarget 7, 60609\u201360622 (2016).","journal-title":"Oncotarget"},{"key":"88983_CR57","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev-pathol-020117-043854","volume":"13","author":"V Mittal","year":"2018","unstructured":"Mittal, V. Epithelial mesenchymal transition in tumor metastasis. Annu. Rev. Pathol. Mech. Dis. 13, 395\u2013412 (2018).","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"88983_CR58","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1128\/MCB.00694-14","volume":"34","author":"D Schaeffer","year":"2014","unstructured":"Schaeffer, D., Somarelli, J. A., Hanna, G., Palmer, G. M. & Garcia-Blanco, M. A. Cellular migration and invasion uncoupled: increased migration is not an inexorable consequence of epithelial-to-mesenchymal transition. Mol. Cell Biol. 34, 3486\u20133499 (2014).","journal-title":"Mol. Cell Biol."},{"key":"88983_CR59","first-page":"1967","volume":"35","author":"TY Ha","year":"2015","unstructured":"Ha, T. Y. et al. Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression. Anticancer Res. 35, 1967\u20131976 (2015).","journal-title":"Anticancer Res."},{"key":"88983_CR60","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/aps.2014.122","volume":"36","author":"JC Wei","year":"2015","unstructured":"Wei, J. C. et al. Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1. Acta Pharmacol. Sin. 36, 241\u2013251 (2015).","journal-title":"Acta Pharmacol. Sin."},{"key":"88983_CR61","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1172\/JCI69738","volume":"124","author":"AC West","year":"2014","unstructured":"West, A. C. & Johnstone, R. W. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 124, 30\u201339 (2014).","journal-title":"J Clin Invest"},{"key":"88983_CR62","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cell.2016.06.028","volume":"166","author":"MA Nieto","year":"2016","unstructured":"Nieto, M. A., Huang, R. Y. Y. J., Jackson, R. A. A. & Thiery, J. P. P. Emt: 2016. Cell 166, 21\u201345 (2016).","journal-title":"Cell"},{"key":"88983_CR63","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1242\/dev.083105","volume":"140","author":"N Reynolds","year":"2013","unstructured":"Reynolds, N., O\u2019Shaughnessy, A. & Hendrich, B. Transcriptional repressors: Multifaceted regulators of gene expression. Development 140, 505\u2013512 (2013).","journal-title":"Development"},{"key":"88983_CR64","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/ijms20122885","volume":"20","author":"M Olea-Flores","year":"2019","unstructured":"Olea-Flores, M. et al. Extracellular-signal regulated kinase: A central molecule driving epithelial-mesenchymal transition in cancer. Int. J. Mol. Sci. 20, 15. https:\/\/doi.org\/10.3390\/ijms20122885 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"88983_CR65","doi-asserted-by":"publisher","first-page":"33156","DOI":"10.1074\/jbc.M113.472506","volume":"288","author":"KA Williams","year":"2013","unstructured":"Williams, K. A. et al. Extracellular signal-regulated kinase (ERK) phosphorylates histone deacetylase 6 (HDAC6) at serine 1035 to stimulate cell migration. J. Biol. Chem. 288, 33156\u201333170 (2013).","journal-title":"J. Biol. Chem."},{"key":"88983_CR66","doi-asserted-by":"publisher","first-page":"867","DOI":"10.3892\/or.2012.1898","volume":"28","author":"K Kanno","year":"2012","unstructured":"Kanno, K. et al. Overexpression of histone deacetylase 6 contributes to accelerated migration and invasion activity of hepatocellular carcinoma cells. Oncol. Rep. 28, 867\u2013873 (2012).","journal-title":"Oncol. Rep."},{"key":"88983_CR67","doi-asserted-by":"publisher","first-page":"7895","DOI":"10.3748\/wjg.v21.i25.7895","volume":"21","author":"Q Pang","year":"2015","unstructured":"Pang, Q. et al. Thrombocytopenia for prediction of hepatocellular carcinoma recurrence: Systematic review and meta-analysis. World J. Gastroenterol. 21, 7895\u20137906 (2015).","journal-title":"World J. Gastroenterol."},{"key":"88983_CR68","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.3748\/wjg.v23.i18.3228","volume":"23","author":"T Kurokawa","year":"2017","unstructured":"Kurokawa, T. & Ohkohchi, N. Platelets in liver disease, cancer and regeneration. World J. Gastroenterol. 23, 3228\u20133239 (2017).","journal-title":"World J. Gastroenterol."},{"key":"88983_CR69","doi-asserted-by":"publisher","first-page":"e1431","DOI":"10.1097\/MD.0000000000001431","volume":"94","author":"Q Pang","year":"2015","unstructured":"Pang, Q. et al. The prognostic value of platelet count in patients with hepatocellular carcinoma. Medicine (Baltimore) 94, e1431 (2015).","journal-title":"Medicine (Baltimore)"},{"key":"88983_CR70","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/hep.26120","volume":"57","author":"A Duffy","year":"2013","unstructured":"Duffy, A., Wilkerson, J. & Greten, T. F. Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies. Hepatology 57, 1068\u20131077 (2013).","journal-title":"Hepatology"},{"key":"88983_CR71","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nprot.2008.73","volume":"3","author":"TD Schmittgen","year":"2008","unstructured":"Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative CT method. Nat. Protoc. 3, 1101\u20131108 (2008).","journal-title":"Nat. Protoc."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88983-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88983-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88983-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T04:16:52Z","timestamp":1698985012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88983-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,5]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["88983"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-88983-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,5]]},"assertion":[{"value":"10 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are employed by 4SC AG which holds patents for resminostat. Hamm S. owns shares in 4SC AG. The research was funded by 4SC AG. The authors acknowledge the infrastructure and support of 4SC AG.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9587"}}